Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model

Emily Z Huie,Xin Yang,Mengia S Rioult-Pedotti,Mandar T Naik,Yu-Wen Alvin Huang,Jill L Silverman,John Marshall

DOI: https://doi.org/10.1101/2024.06.07.597833

2024-06-08

Abstract:Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic factor (BDNF), and its receptor TrkB, have a well-established role as regulators of synaptic plasticity, dendritic outgrowth, dendritic spine formation and maintenance. Previously, we reported that the association of PSD-95 with TrkB is critical for intact BDNF signaling in the AS mouse model, as illustrated by attenuated PLCg and PI3K signaling and intact MAPK pathway signaling. These data suggest that drugs tailored to enhance the TrkB-PSD-95 interaction may provide a novel approach for the treatment of AS and a variety of NDDs. To evaluate this critical interaction, we synthesized a class of high-affinity PSD-95 ligands that bind specifically to the PDZ3 domain of PSD-95, denoted as Syn3 peptidomimetic ligands. We evaluated Syn3 and its analog D-Syn3 (engineered using dextrorotary (D)-amino acids) in vivo using the Ube3a exon 2 deletion mouse model of AS. Following systemic administration of Syn3 and D-Syn3, we demonstrated improvement in the seizure domain of AS. Learning and memory using the novel object recognition assay also illustrated improved cognition following Syn3 and D-Syn3, along with restored long-term potentiation. Finally, D-Syn3 treated mice showed a partial rescue in motor learning. Neither Syn3 nor D-Syn3 improved gross exploratory locomotion deficits, nor gait impairments that have been well documented in the AS rodent models. These findings highlight the need for further investigation of this compound class as a potential therapeutic for AS and other genetic NDDs.

Neuroscience

What problem does this paper attempt to address?

The paper primarily focuses on the study of Angelman Syndrome (AS), a rare genetic neurodevelopmental disorder. AS patients exhibit a variety of severe symptoms, including motor dysfunction, cognitive deficits, and uncontrollable seizures. Currently, there are no effective treatments approved by the U.S. Food and Drug Administration (FDA).

The research team synthesized a novel class of peptidomimetic inhibitors that can target the TrkB/PSD-95 signaling pathway. Specifically, they designed two high-affinity PSD-95 ligands—Syn3 and its analog D-Syn3. These compounds can specifically bind to the PDZ3 domain of PSD-95. By enhancing the interaction between TrkB and PSD-95, the researchers aim to improve cognitive function and seizure conditions in AS mouse models.

In the experiments, the research team used AS mouse models (generated by knocking out exon 2 of the Ube3a gene) and administered Syn3 and D-Syn3 in vivo. The results showed that these compounds significantly improved the cognitive abilities of AS mice (assessed by the novel object recognition test) and seizure threshold. Additionally, D-Syn3 partially restored motor learning abilities in AS mice. However, these treatments did not improve the gross motor exploratory behavior or gait abnormalities of AS mice.

In summary, the main goal of this study is to develop potential new therapies for treating AS, and preliminary results indicate that Syn3 and D-Syn3 may become effective candidate drugs for treating AS and other genetic neurodevelopmental disorders.